Gimeno Isabel M, Cortes Aneg L, Faiz Nik M, Hernandez-Ortiz Byron A, Guy James S, Hunt Henry D, Silva Robert F
A Department of Population Health and Pathobiology, Veterinary School, North Carolina State University, 1060 William Moore Drive, Raleigh, NC 27607.
B U.S. Department of Agriculture, Agricultural Research Service, Avian Disease and Oncology Laboratory, 4279 East Mount Hope Road, East Lansing, MI 48823.
Avian Dis. 2015 Jun;59(2):255-62. doi: 10.1637/10966-103014-Reg.
Laryngotracheitis (LT) is a highly contagious respiratory disease of chickens that produces significant economic losses to the poultry industry. Traditionally, LT has been controlled by administration of modified live vaccines. In recent years, the use of recombinant DNA-derived vaccines using turkey herpesvirus (HVT) and fowlpox virus has expanded, as they protect not only against the vector used but also against LT. However, HVT-based vaccines confer limited protection against challenge, with emergent very virulent plus Marek's disease virus (vv+MDV). Serotype 1 vaccines have been proven to be the most efficient against vv+MDV. In particular, deletion of oncogene MEQ from the oncogenic vvMDV strain Md5 (BACδMEQ) resulted in a very efficient vaccine against vv+MDV. In this work, we have developed two recombinant vaccines against MD and LT by using BACδMEQ as a vector that carries either the LT virus (LTV) gene glycoprotein B (gB; BACΔMEQ-gB) or LTV gene glycoprotein J (gJ; BACδMEQ-gJ). We have evaluated the protection that these recombinant vaccines confer against MD and LT challenge when administered alone or in combination. Our results demonstrated that both bivalent vaccines (BACΔMEQ-gB and BACδMEQ-gJ) replicated in chickens and were safe to use in commercial meat-type chickens bearing maternal antibodies against MDV. BACΔMEQ-gB protected as well as a commercial recombinant (r)HVT-LT vaccine against challenge with LTV. However, BACδMEQ-gJ did not protect adequately against LT challenge or increase protection conferred by BACΔMEQ-gB when administered in combination. On the other hand, both BACΔMEQ-gB and BACδMEQ-gJ, administered alone or in combination, protected better against an early challenge with vv+MDV strain 648A than commercial strains of rHVT-LT or CVI988. Our results open a new avenue in the development of recombinant vaccines by using serotype 1 MDV as vectors.
喉气管炎(LT)是鸡的一种高度传染性呼吸道疾病,给家禽业造成重大经济损失。传统上,LT通过接种改良活疫苗来控制。近年来,使用源自重组DNA的火鸡疱疹病毒(HVT)和禽痘病毒疫苗的情况有所增加,因为它们不仅能抵御所用载体,还能抵御LT。然而,基于HVT的疫苗对超强毒力加马立克氏病病毒(vv+MDV)攻击的保护作用有限。1型血清型疫苗已被证明对vv+MDV最为有效。特别是,从致癌性vvMDV毒株Md5(BACδMEQ)中删除致癌基因MEQ,产生了一种针对vv+MDV的高效疫苗。在这项工作中,我们通过使用BACδMEQ作为载体开发了两种针对MD和LT的重组疫苗,该载体携带LT病毒(LTV)基因糖蛋白B(gB;BACΔMEQ-gB)或LTV基因糖蛋白J(gJ;BACδMEQ-gJ)。我们评估了这些重组疫苗单独或联合使用时对MD和LT攻击的保护作用。我们的结果表明,两种二价疫苗(BACΔMEQ-gB和BACδMEQ-gJ)在鸡体内均可复制,并且对于携带抗MDV母源抗体的商用肉用型鸡来说使用安全。BACΔMEQ-gB对LTV攻击的保护效果与商用重组(r)HVT-LT疫苗相当。然而,BACδMEQ-gJ对LT攻击的保护作用不足,与BACΔMEQ-gB联合使用时也不能增强其保护效果。另一方面,BACΔMEQ-gB和BACδMEQ-gJ单独或联合使用时,对vv+MDV毒株648A早期攻击的保护作用优于商用rHVT-LT或CVI988毒株。我们的研究结果为利用1型MDV作为载体开发重组疫苗开辟了一条新途径。